Home
ChemoCentryx

ChemoCentryx Market Share Analysis for November 2025

at chemocentryx, we believe our patients deserve more than the standard of care available today. so, we are developing our broad portfolio of new medicines using a novel approach to better provide patients with safe, convenient and more effective therapies.

Science and Education > Biology

Domainchemocentryx.com

Year Founded1997

Employees51 - 200

Annual Revenue$25M - $50M

ChemoCentryx

ChemoCentryx (including company regionals)

chemocentryx.com

See more website traffic and engagement information

ChemoCentryx Revenue up to November 2025 is 25M - 50M

revenue generated by ChemoCentryx top domains

ChemoCentryx top domains revenue over 3 years

Revenue for ChemoCentryx top domains

chemocentryx.com25M - 50M

See more with Sales Intelligence

Total visits to ChemoCentryx's top domains

Understand ChemoCentryx market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ChemoCentryx's top domains

Analyze ChemoCentryx engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ChemoCentryx's top domains

See how ChemoCentryx keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ChemoCentryx top competitors by domain

Top similar sites in November 2025, ranked by their affinity

incyte.comCompany NameIncyteEmployees1001 - 5000HQUnited States, Delaware, WilmingtonAnnual revenue> $1BTotal visits99.5KScience and Education > Biology

Top technologies used by ChemoCentryx

These are the website technologies, by industry, used by ChemoCentryx top domains

Widget (5)

Twemoji

Recruitment (3)

WP Job Manager

Advertising (2)

DoubleClick

Content Management System (2)

WordPress

More Technologies

8

See all

News & Signals from ChemoCentryx

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsChemocentryx acquires Horizon Therapeutics plc for $27.8B.In 2022, it acquired ChemoCentryx for $3.7 billion and last year it closed its mammoth $27.8 billion acquisition of Horizon Therapeutics, which gave it access to a promising treatment in Tepezza, which treats thyroid eye disease.

NewsRA Cap files suit against Chemocentryx.RA Capital sues ChemoCentryx after biotech company's $3.9 billion sale to Amgen.

NewsChemocentryx recognized as finalist for best drug launch of 2021 on Aug 22nd '23.His rare disease launch of Tavneos® with ChemoCentryx (now Amgen) was recognized as a finalist for best drug launch of 2021.